암 생물학적 요법 시장 규모, 점유율 및 성장 분석 : 치료법별, 암 유형별, 투여 경로별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Cancer Biological Therapy Market size was valued at USD 108.5 Billion in 2024 and is poised to grow from USD 116.42 Billion in 2025 to USD 204.56 Billion by 2033, growing at a CAGR of 7.3% during the forecast period (2026-2033).

The global market for cancer biological therapy is set to expand significantly, driven by the increasing incidence of cancer and the proliferation of specialized treatment facilities. Experts are innovating with nanotechnology to develop advanced therapeutic solutions, creating opportunities for personalized cancer care. The emphasis on biological therapies and the integration of nanotechnology present transformative potential for cancer treatment, allowing for more tailored and effective patient outcomes. As research and technological advancements continue to progress in this field, the market for cancer biological therapy is poised for remarkable growth, enhancing efforts in the ongoing battle against cancer and improving the overall landscape of cancer care globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Biological Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Biological Therapy Market Segments Analysis

Global Cancer Biological Therapy Market is segmented by Therapy Type, Cancer Type, Route of Administration, Distribution Channel and region. Based on Therapy Type, the market is segmented into Monoclonal Antibodies, Cancer Vaccines, Cytokine Therapy, Adoptive Cell Transfer, Immune Checkpoint Inhibitors, Targeted Cancer Growth Blockers, Blood Cell Growth Factors (BCGF), Oncolytic Virus Therapy, Gene Therapy and Other Therapy Types. Based on Cancer Type, the market is segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Pancreatic Cancer, Ovarian Cancer and Other Cancer Types. Based on Route of Administration, the market is segmented into Intravenous (IV), Subcutaneous, Intratumoral, Oral and Others. Based on Distribution Channel, the market is segmented into Online Pharmacies, Retail Pharmacies and Hospital Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Biological Therapy Market

The escalating incidence of cancer across the globe significantly propels the expansion of the global cancer biological therapy market. The rise in cases, particularly of Small Cell Lung Cancer (SCLC), predominantly affects individuals in their sixties to eighties, highlighting a pressing healthcare challenge. The substantial mortality associated with SCLC and the prevalence of lung cancer as a leading cause of cancer-related deaths further underline the urgent need for innovative treatment options. These factors create a heightened demand for cancer biological therapies, as stakeholders seek effective solutions to manage and combat the growing cancer burden worldwide, thereby driving the market's progress.

Restraints in the Global Cancer Biological Therapy Market

The high financial burden linked to cancer treatment methods creates a notable obstacle for the expansion of the Global Cancer Biological Therapy market. The elevated costs of these therapies can be prohibitive, particularly for individuals in economically disadvantaged or rural regions, limiting their access to potentially life-saving treatments. This affordability issue significantly restricts the market's reach, as numerous patients may opt for less effective or alternative remedies due to financial constraints. Consequently, this challenges the overall development of the market and hampers its ability to provide necessary therapies to a broader population in need.

Market Trends of the Global Cancer Biological Therapy Market

The global cancer biological therapy market is experiencing a significant trend towards personalized and targeted treatment modalities, driven by advancements in genomics and molecular biology. As the unique genetic and molecular characteristics of tumors become increasingly well-documented, the development of biological therapies tailored to address specific genetic abnormalities and biomarkers has gained prominence. This customization leads to improved patient outcomes, minimized side effects, and enhanced therapeutic efficacy. By concentrating on the underlying molecular mechanisms responsible for tumor growth and proliferation, these innovative therapies are revolutionizing cancer treatment, enabling more precise and effective management of various cancer types, thereby reshaping the therapeutic landscape in oncology.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impact Factor
• Top Investment Pockets
• Market Attractiveness Index
• Market Ecosystem
• PESTEL Analysis
• Regulatory Landscape
• Case Study Analysis
• Value Chain Analysis
• Patent Analysis
• Technology Analysis
• Clinical Trial Analysis
• Disease Epidemiology

Global Cancer Biological Therapy Market Size by Therapy Type (2019-2032)

• Market Overview
• Monoclonal Antibodies
  • Naked MAB
  • Conjugated MAB
  • Bispecific MAB
• Cancer Vaccines
  • Preventive Vaccines
  • Therapeutic Vaccines
• Cytokine Therapy
  • Interleukins
  • Interferons
• Adoptive Cell Transfer
  • CAR T-cell therapy
  • Tumor-Infiltrating Lymphocytes
  • TCR therapy
• Immune Checkpoint Inhibitors
  • PD-1/PD-L1 inhibitors
  • CTLA-4 inhibitors
• Targeted Cancer Growth Blockers
  • Tyrosine Kinase Inhibitors (TKIs)
  • Proteasome Inhibitors (PIs)
  • mTOR Inhibitors
• Blood Cell Growth Factors (BCGF)
  • Lenograstim
  • Filgrastim
  • Other BCGF
• Oncolytic Virus Therapy
• Gene Therapy
• Other Therapy Types

Global Cancer Biological Therapy Market Size by Cancer Type (2019-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Pancreatic Cancer
• Ovarian Cancer
• Other Cancer Types

Global Cancer Biological Therapy Market Size by Route of Administration (2019-2032)

• Market Overview
• Intravenous (IV)
• Subcutaneous
• Intratumoral
• Oral
• Others

Global Cancer Biological Therapy Market Size by Distribution Channel (2019-2032)

• Market Overview
• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

Global Cancer Biological Therapy Market Size (2019-2032)

• North America (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
  • US
  • Canada
• Europe (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Dashboard

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Product Portfolio Overview
  • Financial Overview
  • Key Developments
• The following companies are listed for indicative purposes only. Similar information will be provided for each, with detailed financial data available exclusively for publicly listed companies.
• Merck & Co.
• Bristol Myers Squibb
• F. Hoffmann-La Roche Ltd
• Novartis AG
• AstraZeneca
• Amgen Inc.
• Eli Lilly and Company
• Sanofi
• AbbVie Inc.
• GlaxoSmithKline Plc.
• Bayer AG
• Exelixis Inc.
• Incyte
• BioNTech SE
• Adaptimmune
• Nanobiotix
• Vir Biotechnology Inc.
• Innate Pharma Inc.
• AdcentrX Therapeutics

Conclusion & Analyst Recommendations